Three of the five individual TAAs, FKBP52, PPIA, and PRDX2, showed significantly increased reactivity in breast carcinoma patients and breast carcinoma in situ patients compared to healthy controls. The gene discussed is PPIA; the disease is lobular breast carcinoma in situ.